Roche CEO Cautious on Alzheimer’s Trial Despite Eisai’s Success
This article is for subscribers only.
Roche Holding AG’s chief executive officer cautioned that groundbreaking results for an Alzheimer’s disease treatment from a rival drugmaker don’t necessarily mean the Swiss company will be able to deliver similar success in its own upcoming clinical trial.
“It is very dangerous to cross-read on trials,” Chief Executive Severin Schwan said in a briefing for reporters on Tuesday. “We have to wait for the readout, and then we can take it from there.”